150 related articles for article (PubMed ID: 34282791)
41. Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.
Bearz A; Martini JF; Jassem J; Kim SW; Chang GC; Shaw AT; Shepard DA; Dall'O' E; Polli A; Thurm H; Zalcman G; Garcia Campelo MR; Penkov K; Hayashi H; Solomon BJ
J Thorac Oncol; 2023 Nov; 18(11):1581-1593. PubMed ID: 37541389
[TBL] [Abstract][Full Text] [Related]
42. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
43. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
[TBL] [Abstract][Full Text] [Related]
44. The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples.
Van Paemel R; Vandeputte C; Raman L; Van Thorre J; Willems L; Van Dorpe J; Van Der Linden M; De Wilde J; De Koker A; Menten B; Devalck C; Vicha A; Grega M; Schleiermacher G; Iddir Y; Chicard M; van Zogchel L; Stutterheim J; Lak NSM; Tytgat GAM; Laureys G; Speleman F; De Wilde B; Lammens T; De Preter K; Van Roy N
Eur J Cancer; 2022 Jan; 160():12-23. PubMed ID: 34794856
[TBL] [Abstract][Full Text] [Related]
45. Oncogenic mutations of ALK kinase in neuroblastoma.
Chen Y; Takita J; Choi YL; Kato M; Ohira M; Sanada M; Wang L; Soda M; Kikuchi A; Igarashi T; Nakagawara A; Hayashi Y; Mano H; Ogawa S
Nature; 2008 Oct; 455(7215):971-4. PubMed ID: 18923524
[TBL] [Abstract][Full Text] [Related]
46. Diagnostic accuracy of circulating-free DNA for the determination of MYCN amplification status in advanced-stage neuroblastoma: a systematic review and meta-analysis.
Trigg RM; Turner SD; Shaw JA; Jahangiri L
Br J Cancer; 2020 Mar; 122(7):1077-1084. PubMed ID: 32015512
[TBL] [Abstract][Full Text] [Related]
47. Plasma circulating cell-free MYCN gene: A noninvasive and prominent recurrence monitoring indicator of neuroblastoma.
Liang Y; Liu Y; Zhang P; Zhang M; Du B; Cheng W; Yu Z; Li L; Wang H; Hou G; Zhang X; Zhang W
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1688. PubMed ID: 35892165
[TBL] [Abstract][Full Text] [Related]
48. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
49. High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset.
Carén H; Kryh H; Nethander M; Sjöberg RM; Träger C; Nilsson S; Abrahamsson J; Kogner P; Martinsson T
Proc Natl Acad Sci U S A; 2010 Mar; 107(9):4323-8. PubMed ID: 20145112
[TBL] [Abstract][Full Text] [Related]
50. Association between circulating tumor DNA burden and disease burden in patients with ALK-positive lung cancer.
Zhang EW; Dagogo-Jack I; Kuo A; Rooney MM; Shaw AT; Digumarthy SR
Cancer; 2020 Oct; 126(20):4473-4484. PubMed ID: 32757294
[TBL] [Abstract][Full Text] [Related]
51. Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction.
Lee JS; Kim M; Seong MW; Kim HS; Lee YK; Kang HJ
Clin Chem Lab Med; 2020 Mar; 58(4):527-532. PubMed ID: 31874093
[TBL] [Abstract][Full Text] [Related]
52. Radiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survival.
Brisse HJ; Blanc T; Schleiermacher G; Mosseri V; Philippe-Chomette P; Janoueix-Lerosey I; Pierron G; Lapouble E; Peuchmaur M; Fréneaux P; Galmiche L; Algret N; Peycelon M; Michon J; Delattre O; Sarnacki S
PLoS One; 2017; 12(9):e0185190. PubMed ID: 28945781
[TBL] [Abstract][Full Text] [Related]
53. Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment.
Bordi P; Tiseo M; Rofi E; Petrini I; Restante G; Danesi R; Del Re M
Clin Lung Cancer; 2017 Nov; 18(6):692-697. PubMed ID: 28601386
[TBL] [Abstract][Full Text] [Related]
54. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
55. Development of Highly Sensitive Digital Droplet PCR for Detection of cKIT Mutations in Circulating Free DNA That Mediate Resistance to TKI Treatment for Gastrointestinal Stromal Tumor (GIST).
Rassner M; Waldeck S; Follo M; Jilg S; Philipp U; Jolic M; Wehrle J; Jost PJ; Peschel C; Illert AL; Duyster J; Scherer F; von Bubnoff N
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982486
[TBL] [Abstract][Full Text] [Related]
56. Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors.
Bagci O; Tumer S; Olgun N; Altungoz O
Cancer Lett; 2012 Apr; 317(1):72-7. PubMed ID: 22085494
[TBL] [Abstract][Full Text] [Related]
57. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
58. Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment.
Beagan JJ; Bach S; van Boerdonk RA; van Dijk E; Thunnissen E; van den Broek D; Weiss J; Kazemier G; Pegtel DM; Bahce I; Ylstra B; Heideman DAM
Lung Cancer; 2020 Jul; 145():173-180. PubMed ID: 32460198
[TBL] [Abstract][Full Text] [Related]
59. Distribution of segmental chromosomal alterations in neuroblastoma.
Juan Ribelles A; Gargallo P; Ferriol C; Segura V; Yáñez Y; Juan B; Cañada AJ; Font de Mora J; Cañete A; Castel V
Clin Transl Oncol; 2021 Jun; 23(6):1096-1104. PubMed ID: 32948984
[TBL] [Abstract][Full Text] [Related]
60. Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma.
Bustamante P; Tsering T; Coblentz J; Mastromonaco C; Abdouh M; Fonseca C; Proença RP; Blanchard N; Dugé CL; Andujar RAS; Youhnovska E; Burnier MN; Callejo SA; Burnier JV
J Exp Clin Cancer Res; 2021 Jun; 40(1):196. PubMed ID: 34134723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
